EFTR Stock Overview
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Earnings are forecast to decline by an average of 29.6% per year for the next 3 years
+ 2 more risks
My Notes
NewNotes are coming soon
eFFECTOR Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.48 |
| 52 Week High | US$5.97 |
| 52 Week Low | US$0.36 |
| Beta | 0 |
| 1 Month Change | 14.69% |
| 3 Month Change | -22.27% |
| 1 Year Change | -91.43% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -95.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| EFTR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.7% | 0.7% | 2.3% |
| 1Y | -91.4% | 7.1% | -9.7% |
Return vs Industry: EFTR underperformed the US Biotechs industry which returned 10.5% over the past year.
Return vs Market: EFTR underperformed the US Market which returned -8.5% over the past year.
Price Volatility
| EFTR volatility | |
|---|---|
| EFTR Average Weekly Movement | 19.3% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: EFTR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: EFTR's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 12 | Steve Worland | https://effector.com |
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors.
eFFECTOR Therapeutics, Inc. Fundamentals Summary
| EFTR fundamental statistics | |
|---|---|
| Market Cap | US$20.18m |
| Earnings (TTM) | US$5.64m |
| Revenue (TTM) | US$3.19m |
3.6x
P/E Ratio6.3x
P/S RatioIs EFTR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EFTR income statement (TTM) | |
|---|---|
| Revenue | US$3.19m |
| Cost of Revenue | US$23.06m |
| Gross Profit | -US$19.87m |
| Other Expenses | -US$25.51m |
| Earnings | US$5.64m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.13 |
| Gross Margin | -623.02% |
| Net Profit Margin | 176.98% |
| Debt/Equity Ratio | 173.7% |
How did EFTR perform over the long term?
See historical performance and comparison